<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315066</url>
  </required_header>
  <id_info>
    <org_study_id>B0601002</org_study_id>
    <secondary_id>2014-004107-75</secondary_id>
    <secondary_id>B0601002</secondary_id>
    <nct_id>NCT02315066</nct_id>
  </id_info>
  <brief_title>Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566</brief_title>
  <official_title>A Phase 1, Open-label, Dose Escalation Study Of Pf-04518600 As A Single Agent And In Combination With Pf-05082566 In Patients With Selected Locally Advanced Or Metastatic Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in
      combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in
      order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose-limiting toxicities (DLT) [Dose Escalation]</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>First and second cycle DLTs in order to determine maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall safety profile [Dose Expansion]</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>Type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and any laboratory abnormalities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies and neutralization assays</measure>
    <time_frame>0 hr on Day 1 Cycles 1 to 4, 7 and every other cycle</time_frame>
    <description>Number of participants with the presence of anti-PF-04518600 antibodies and neutralization assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response</measure>
    <time_frame>Baseline, every 6 weeks (Part 1) or 8 weeks (Part 2) until disease progression or unacceptable toxicity</time_frame>
    <description>Number of participants with objective response based on assessment of progression free survival (PFS), time to progression (TTP), duration of stable disease (SD), duration of response (DR) according to RECIST version 1.1 and irRECIST and overall survival (OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound (free) cell surface OX40 in peripheral blood</measure>
    <time_frame>0 hr and scheduled timepoints post dose on Cycles 1 to 3, then 0hr on cycles 4 and 7</time_frame>
    <description>Levels of free OX40 receptor expressed on T cells in peripheral blood after dosing with PF 04518600 alone or in combination with PF 05082566.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0 hr and scheduled timepoints post dose on Cycles 1 to 6, then 0hr on every cycle</time_frame>
    <description>Cmax will be calculated for PF-04518600 and PF-05082566</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve (AUCt)</measure>
    <time_frame>0 hr and scheduled timepoints post dose on Cycles 1 to 6, then 0hr on every cycle</time_frame>
    <description>Area under the plasma concentration versus time curve will be calculated for PF-04518600 and PF-05082566</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>PF-04518600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OX40 agonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-04518600 plus PF-05082566</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OX40 (CD134) agonist plus 4-1BB (CD137) agonist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600</intervention_name>
    <description>Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined</description>
    <arm_group_label>PF-04518600</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600</intervention_name>
    <description>Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously</description>
    <arm_group_label>PF-04518600</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600 plus PF-05082566</intervention_name>
    <description>Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.</description>
    <arm_group_label>PF-04518600 plus PF-05082566</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600 plus PF-05082566</intervention_name>
    <description>Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.</description>
    <arm_group_label>PF-04518600 plus PF-05082566</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part A1 only: Patients with histological or cytological diagnosis of HNSCC, HCC,
             melanoma, or clear cell RCC who progressed on or are intolerant to standard therapy,
             for which no standard therapy is available or who decline standard therapy.

          -  Part A2 only: Patients with histological or cytological diagnosis of HCC who have had
             0 to 2 prior lines of systemic therapy (progressed or intolerant to approved HCC
             standard of care treatment).

          -  Part B1 only: Patients with histological or cytological diagnosis of NSCLC, HNSCC,
             melanoma, urothelial bladder carcinoma (including renal pelvis, ureters, urinary
             bladder, and urethra), gastric or squamous cell carcinoma of the uterine cervix who
             progressed on or are intolerant to standard therapy, for which no standard therapy is
             available, or who decline standard therapy.

          -  Part B2

        Arm 1 only:

          1. Ocular melanoma; and have received no more than one line of systemic therapy for
             metastatic disease. Patients must not have received immune modifying agents (eg. anti
             PD-L1, anti PD-1, anti CTLA4, TNF agonist, etc.) for metastatic disease, or

          2. Cutaneous/acral melanoma; and have 1) only previously received systemic therapy for
             advanced/metastatic disease with the following therapies: BRAF and MEK inhibitors,
             anti PD-L1, anti PD-1, or anti-CTLA4 and 2) have received checkpoint inhibitor (anti
             PD-L1, anti PD-1, or anti-CTLA4) based treatment as most recent line of therapy on
             which disease progressed, as long as progression did not occur in the first 3 months
             of receiving checkpoint inhibitor treatment.

        Arm 2 only:

          -  Histological or cytological diagnosis of NSCLC. Patients must have 1) previously
             received prior anti-PD-L1 or anti-PD-1 mAb as most recent therapy, AND 2) did not have
             progressive disease as best overall response on recent PD-L1/PD-1 therapy (ie, stable
             disease 3 months, PR, or CR), AND 3) who subsequently progressed on anti-PD-L1 or
             anti-PD-1 mAb.

          -  Performance Status of 0 or 1 - Adequate bone marrow, kidney and liver function

        Exclusion Criteria:

          -  Brain metastases requiring steroids

          -  Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
             study treatment start (6 weeks for mitomycin C or nitrosoureas)

          -  Active and clinically significant bacterial, fungal, or viral infection

          -  History of active autoimmune disorders

          -  History of immune-mediated adverse events requiring immunosuppressive therapy or were
             grade 3 or higher related to prior immune-modulatory therapy

          -  Prior treatment with an OX40 agonist and 4-1BB agonist (for Part B1/B2)

          -  Prior anthracycline treatment and at risk of cardiac failure (New York Heart
             Association Class 2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LAC+USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ronald Regan Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology &amp; Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Imaging Center of Southern California, Inc.</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santa Monica UCLA Hematology &amp; Oncology Clinic</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UConn Health, Pharmacy</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-2205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UConn Health, Neag Comprehensive Cancer Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (MGH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital (BWH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (BIDMC)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Herbert Irving Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CUMC Research Pharmacy</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital-Pathology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance (Drug Shipment Address)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre D'Investigation Clinique (CIC)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laboratory research biomedical (LRBM)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy- Pharmacie-Unite Essais Cliniques</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Slotervaart Hospital/Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Cancer Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0601002&amp;StudyName=</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2014</study_first_submitted>
  <study_first_submitted_qc>December 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>PF-04518600</keyword>
  <keyword>PF-05082566</keyword>
  <keyword>solid tumors</keyword>
  <keyword>tumors</keyword>
  <keyword>neoplasm metastasis</keyword>
  <keyword>Phase 1</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>liver cancer</keyword>
  <keyword>ocular melanoma</keyword>
  <keyword>melanoma</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>RCC</keyword>
  <keyword>kidney cancer</keyword>
  <keyword>head and neck squamous cell carcinoma</keyword>
  <keyword>HNSCC</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>cancer of the cervix</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>stomach cancer</keyword>
  <keyword>non small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>lung cancer</keyword>
  <keyword>urothelial bladder carcinoma</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>OX40</keyword>
  <keyword>4-1BB</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

